Host: Larry Kaskel, MD

Guest: Eliot Brinton

Results from the recent JUPITER trial demonstrated that high-sensitivity C-reactive protein tests were strikingly effective at identifying patients whose risk of cardiovascular events and mortality could be significantly lowered with statin treatment. But do these results warrant broader screening for C-reactive protein, as some suggest? Join host Dr. Larry Kaskel and Dr. Eliot Brinton as they critically examine the JUPITER trial and the potential limitations of those findings for primary care physicians and the use of statins.

Brought to you by: